Quantum BioPharma Overview
Quantum BioPharma (QNTM) has a ROE of -314.05%, below the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow-314.05%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for QNTM is -314.05%. That is below the sector sector average of -5.68%. Investors often review this figure alongside Quantum BioPharma's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, QNTM currently prints -314.05% for ROE, while the sector average sits near -5.68%. That is roughly 5426.0% below the sector mean. Large gaps often invite a closer look at Quantum BioPharma's growth, margins, and balance sheet.
Return on Equity shows how effectively Quantum BioPharma converts resources into returns. At -314.05%, QNTM may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting QNTM's ROE (-314.05%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
